SINGAPORE: The updated JN.1 Novavax/Nuvaxovid COVID-19 vaccine will be offered under the national vaccination programme at ...

The U.S. Department of Health and Human Services has awarded Moderna (MRNA) $590M to “advance the late-stage development of its mRNA bird flu ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

We recently compiled a list of the 10 Best High-Yield Dividend Stocks To Invest In. In this article, we are going to take a ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

The U.S. Department of Health and Human Services or HHS said it will provide approximately $590 million to Moderna (MRNA) to ...

Dylan Lewis: We're talking three stocks down bad. Motley Fool Money starts down. I'm Dylan Lewis, I'm joined over the ...

Adar Poonawalla, CEO, Serum Institute of India talks to Arijit Barman about a range of issues including the impact of Trump’s ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near future ...

Biotech has lagged even more. The S&P Biotechnology Select Industry Index has returned about 3 per cent annually over 10 ...

Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of ...